Compare TBPH & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | GDRX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 702.3M |
| IPO Year | 2013 | 2020 |
| Metric | TBPH | GDRX |
|---|---|---|
| Price | $16.45 | $2.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $18.40 | $3.86 |
| AVG Volume (30 Days) | 528.6K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 125.00 |
| EPS | ★ 2.06 | 0.09 |
| Revenue | $15,386,000.00 | ★ $796,853,000.00 |
| Revenue This Year | $1.04 | N/A |
| Revenue Next Year | N/A | $5.38 |
| P/E Ratio | ★ $8.05 | $22.94 |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $8.12 | $1.77 |
| 52 Week High | $21.03 | $5.61 |
| Indicator | TBPH | GDRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 46.18 |
| Support Level | $13.41 | $1.77 |
| Resistance Level | $19.04 | $2.47 |
| Average True Range (ATR) | 0.53 | 0.09 |
| MACD | 0.37 | 0.01 |
| Stochastic Oscillator | 99.04 | 51.56 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.